Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00834431 | Famciclovir 500 mg Tablets Under Fasting Conditions | PHASE1 | COMPLETED | 36 | — | — | Aug 1, 2004 | Sep 1, 2004 | Aug 20, 2024 | 2 | United States, Canada |
| NCT00834444 | Famciclovir 500 mg Tablets Under Non-Fasting Conditions | PHASE1 | COMPLETED | 36 | — | — | Aug 1, 2004 | Sep 1, 2004 | Aug 20, 2024 | 2 | United States, Canada |
Bioequivalence based on Cmax.
Bioequivalence based on AUC0-t.
Bioequivalence based on AUC0-inf.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Famciclovir 500 mg Tablets | DRUG | 1 x 500 mg, single-dose fasting |
| Famvir® 500 mg Tablets | DRUG | 1 x 500 mg, single-dose fasting |
Inclusion Criteria: * All subjects selected for this study will be at least 18 years of age. * Each subject shall be given a general physical examination within 28 days of initiation of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history. *...